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Akt is a serine/threonine protein kinase that is acti-
vated by a variety of growth factors or cytokines in a
phosphatidylinositol 3-kinase–dependent manner.
By using a conditional transgenic system in which Akt
signaling can be turned on or off in the adult heart,
we previously showed that short-term Akt activation
induces a physiological form of cardiac hypertrophy
with enhanced coronary angiogenesis and maintained
contractility. Here we tested the hypothesis that induc-
tion of physiological hypertrophy by short-term Akt
activation might improve contractile function in failing
hearts. When Akt signaling transiently was activated in
murine hearts with impaired contractility, induced by
pressure overload or doxorubicin treatment, contractile
dysfunction was attenuated in both cases. Impor-
tantly, improvement of contractility was observed be-
fore the development of cardiac hypertrophy, indicat-
ing that Akt activation improves contractile function
independently of its growth-promoting effects. To
gain mechanistic insights into Akt-mediated positive
inotropic effects, transcriptional profiles in the heart
were determined in a pressure overload–induced
heart failure model. Biological network analysis of
differentially expressed transcripts revealed signifi-
cant alterations in the expression of genes associated
with cell death, and these alterations were reversed
by short-term Akt activation. Thus, short-term Akt
activation improves contractile function in failinghearts. This beneficial effect of Akt on contractility is
hypertrophy-independent and may be mediated in
part by inhibition of cell death associated with heart
failure. (Am J Pathol 2012, 181:1969–1976; http://dx.doi.
org/10.1016/j.ajpath.2012.08.020)
Heart failure is a major cause of mortality and morbidity
worldwide.1–4 One common feature of heart failure is
hypertrophy of individual cardiac muscle cells in the myo-
cardium.5–8 Cardiac hypertrophy observed in patients
with hypertension, myocardial infarction, or valvular heart
disease is considered to be an adaptive response be-
cause hypertrophy can normalize the increase in wall
stress induced by mechanical overload. However, in-
creased cardiac mass is clinically associated with in-
creased morbidity and mortality,9 and sustained overload
eventually leads to contractile dysfunction and heart fail-
ure.10–12 Thus, stress-induced or pathologic cardiac
hypertrophy appears to be detrimental for the heart. Con-
versely, normal postnatal growth of the heart or exercise-
induced cardiac growth also occurs through hypertrophy
of individual cardiac muscle cells. These forms of so-
called physiological cardiac hypertrophy are associated
with normal or enhanced contractile function and are
morphologically and molecularly distinct from stress-in-
duced hypertrophy.13,14
Akt is a serine/threonine protein kinase that mediates
cellular growth responses in multiple organisms and cell
types.15,16 There are three Akt genes in mammalian ge-
nomes (Akt1/PKB, Akt2/PKB, and Akt3/PKB). Loss of
Akt1 gene in mice leads to general growth retardation
and spontaneous apoptosis in restricted cell types.17,18
Akt2 gene disruption results in abnormal glucose metab-
olism and mild growth deficiency,19,20 whereas Akt3
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brain.21,22 Furthermore, these genes display a consider-
able degree of functional overlap, exemplified by the
combined deletion of Akt1 and Akt2 genes, which results
in perinatal lethality with severe growth retardation and
multiple developmental defects23 and by Akt1/Akt3 dou-
ble-knockout mice, which are embryonic-lethal owing to a
placental defect.24 In the heart, Akt is an important pos-
itive regulator of normal postnatal cardiac growth25 and
also is activated by exercise training,26–28 by pressure
overload,29 and is activated in diseased human hearts.30
Overexpression of activated Akt1 or Akt3 in the heart is
sufficient to induce cardiac hypertrophy and, in some
cases, heart failure in transgenic (TG) mice.31–34 These
data suggest that Akt-dependent signaling pathways are
involved in both physiologic and pathologic cardiac
growth.
By using a conditional TG system, in which the ex-
pression of the Akt transgene can be turned on or off at
desired time points, we previously showed that short-
term Akt activation induces physiologic hypertrophy
but long-term Akt activation leads to pathologic hyper-
trophy and heart failure.35 In cardiac hypertrophy in-
duced by short-term Akt activation, contractile function
was preserved. Because physiologic hypertrophy can
be adaptive by reducing wall stress without adverse
effects on contractile function, we tested the hypothe-
sis that induction of physiologic hypertrophy by short-
term Akt activation might attenuate contractile dysfunc-
tion in failing hearts. We show that transient Akt
activation improves contractile function in two different
heart failure models and we explored the potential
mechanisms of Akt-mediated positive inotropic effects
by transcriptome analysis.
Materials and Methods
Animals
Generation, genotyping, and the initial characterization of
cardiac-specific inducible Akt TG mice have been de-
scribed previously.35 In brief, two lines of TG mice (tet-
Akt and MHC-tTA) were crossed to generate double-TG
(DTG) mice. When DTG mice are treated with doxycy-
cline (DOX), the expression of Akt transgene is turned off.
When DOX is withdrawn, Akt transgene expression is
induced specifically in the heart. MHC-tTA single-TG
mice were used as controls and treated with DOX in the
same manner as DTG animals.
Heart Failure Models
For pressure overload–induced heart failure models,
mice were subjected to ascending aorta constriction
(AAC) at the age of 8 weeks as described previously.36
DOX was withdrawn at the age of 12 weeks (4 weeks after
AAC) to induce Akt transgene expression in the heart.
DOX had been given continuously since before birth.
Echocardiography was performed at the age of 8 (beforeAAC), 12 (4 weeks after AAC), 13 (1 week after Akt
activation), and 14 weeks (2 weeks after Akt activation).
For Adriamycin (ADR; Sigma-Aldrich, St. Louis, MO)-in-
duced heart failure models, ADR was administered to
12-week-old mice in 3 equal intraperitoneal injections for
2 weeks (8 mg/kg for a single injection, cumulative dose
of 24 mg/kg body weight). DOX was withdrawn at the age
of 16 weeks (4 weeks after initial ADR injection) to induce
Akt transgene in the heart. DOX had been given contin-
uously since before birth. Echocardiography was per-
formed at the age of 12 (before ADR injection), 16 (4
weeks after initial ADR injection), 17 (1 week after Akt
activation), and 18 weeks (2 weeks after Akt activation).
Echocardiography
Transthoracic echocardiography was performed with an
ACUSON 256 sector scanner (Siemens, Mountain View,
CA) equipped with a 13-MHz transducer as described
previously.35
Microarray Analysis
Transcriptional profiles were determined in pressure
overload–induced heart failure models. Mice were sac-
rificed at predetermined time points. Hearts were ex-
cised and snap-frozen in liquid nitrogen. RNA extrac-
tion, cDNA synthesis, biotinylated cRNA preparation,
and hybridization of cRNA to microarrays (GeneChip
Mouse Expression Set 430; Affymetrix, Santa Clara,
CA) were performed as described.37–39 Data were ob-
tained at three time points [before AAC, 4 weeks after
AAC, and 6 weeks after AAC (2 weeks after Akt acti-
vation)], and four independent sets of hybridizations
were performed at each time point. An automated anal-
ysis of related transcripts was performed using Inge-
nuity Pathways Analysis (Redwood City, CA), a web-
delivered application that evaluates biological
networks. Data analysis was performed as de-
scribed.37–39 In addition, automated analysis of groups
of biologically related genes was performed using
GenMAPP and MAPPFinder version 2.0 (http://www.
genmapp.org) as described.37 MAPPFinder is a tool
that integrates the annotations of the Gene Ontology
Project (http://www.geneontology.org) with the free
software package Gen-MAPP. MAPPFinder identifies
Gene Ontology Project terms with overrepresented
numbers of gene-expression charges. GenMAPP gen-
erates graphic files within which gene expression data
can be viewed in the context of the biological knowl-
edge contained in the Gene Ontology Project data-
base.
qPCR Analysis
Expression levels of selected transcripts were examined
by quantitative real-time PCR (qPCR) as described.37The primers in Table 1 were used for qPCR analysis.
TTTCC
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Improvement of Contractile Function by
Transient Akt Activation
To examine the effects of inducible Akt activation in failing
hearts, mice were subjected to AAC at the age of 8 weeks
and Akt transgene was induced by withdrawing DOX at
the age of 12 weeks, when contractile dysfunction was
apparent by echocardiography (Figure 1). At the age of
13 weeks (1 week after Akt activation), there was a sig-
nificant increase in the percentage of fractional shorten-
ing in DTG animals compared with control animals. This
improvement of contractility was maintained at 14 weeks
of age (2 weeks after Akt activation). Of note, there was a
significant increase in posterior wall thickness in DTG
mice compared with control animals at 14 weeks old but
not at 13 weeks old. This is consistent with our previous
observation that a significant increase in heart weight
starts to be observed at day 10 after Akt transgene in-
duction.35 These findings indicate that transient Akt acti-
vation in failing hearts leads to improvement of contractile
function, and this positive inotropic effect of Akt activation
is independent of its growth-promoting effect.
To examine whether this beneficial effect of Akt on
contractility is observed in a different form of heart failure,
Table 1. qPCR Analysis. Expression levels of selected transcripts
Transcript F
Actin  1 5’-TGCGCGAC
ATP-binding cassette, sub-family A (ABC1),
member 4
5’-GTCCTCAG
BCL2-like 11 5’-GCCCCTAC
Bone morphogenetic protein 8b 5’-GCCCCTCG
Calsequestrin 1 5’-CAAGGTGG
Carboxylesterase 3 5’-CAGCCTGT
Cartilage intermediate layer protein,
nucleotide pyrophosphohydrolase
5’-GATGCCCA
Cullin 5 5’-AGACTCCA
Cyclin B2 5’-CACTTTAG
Cytokine receptor-like factor 1 5’-TCACCACC
Fast skeletal myosin alkali light chain 5’-ACAAGGAC
Fibroblast growth factor 4 5’-CTACCTGC
Fibrillin 1 5’-GCCCTGCT
Follistatin related protein 5’-CAAGTGCC
Gap junction membrane channel protein 1 5’-CAGCCTGA
Glucosaminyl (N-acetyl) transferase 1, core 2 5’-GCTGGAGA
Histocompatibility 2, L region 5’-CGACGGCT
Insulin-like growth factor binding protein 1 5’-CCGCGGAT
Insulin-like growth factor binding protein 5 5’-GAAGGACC
Mitogen activated protein kinase 13 5’-ACTGGCTC
Myomesin 2 5’-CCTGCCTA
Myotrophin 5’-GCTGTCTA
Ninjurin 1 5’-GGTGGAGC
Phospholipase A2, group IIC 5’-CCTCCACC
Procollagen, type V,  1 5’-GATGGCAT
Procollagen, type VIII,  1 5’-CCAGGGAG
Prolactin receptor 5’-GCCTTCCA
Prostaglandin D2 synthase 5’-TCCGGGAG
SRY-box containing gene 4 5’-CAAGCGGC
Tenascin C 5’-ACAGCTAC
Thrombospondin 1 5’-CAACGTCC
Thymoma viral proto-oncogene 1 5’-CCTTCCTT
Zinc finger protein 352 5’-GCCATTGGAkt transiently was activated in failing hearts induced byADR treatment. Mice received three injections of ADR
once a week beginning at the age of 12 weeks. Akt
transgene was induced by withdrawing DOX at the age of
16 weeks (Figure 2). At this time point, contractile dys-
function was apparent by echocardiography. As was the
case with pressure overload–induced heart failure, tran-
sient Akt activation in cardiac muscle cells improved
ADR-induced contractile function, and this beneficial ef-
fect of Akt was independent of its growth-promoting ef-
fect because there was a significant increase in the per-
centage of fractional shortening at the age of 17 weeks (1
week after Akt activation) when there was no increase in
wall thickness. Taken together, Akt activation improves
contractile function in two different models of heart failure
independently of its growth-promoting effect on the myo-
cardium.
Microarray Analysis of Differentially Expressed
Genes
To gain insights into Akt-mediated, positive inotropic ef-
fects, transcriptional profiles in the heart were determined
in a pressure overload–induced heart failure model. RNA
samples were prepared at 8 weeks (time point 1: before
AAC), 12 weeks (time point 2: 4 weeks after AAC when
xamined by qPCR as described.37
primer Reverse primer
AGAGAAG-3’ 5’-ACCGATAAAGGAAGGCTGGAA-3’
TGCAATCGA-3’ 5’-CAGGCGGTCAGCGTAGAGA-3’
TACAGACA-3’ 5’-CCGCAGCTCCTGTGCAAT-3’
CAAGAC-3’ 5’-TGCCTGCGGCAAACTTCT-3’
AAGCTGACT-3’ 5’-CCTCCACGAAGCTCACAATCTC-3’
TTTTCCT-3’ 5’-CCTGCCCTCCAACAGCAT-3’
AGCCTGAAGT-3’ 5’-GGTTTCCCCGTGGCTTTG-3’
GTGCAATGA-3’ 5’-CCTCTCTGTTGAGTCCAAGTATGC-3’
TACCTGATGGA-3’ 5’-GCCTGTGTAATACTGCTGCTTCA-3’
TCAAGGATT-3’ 5’-GCACTTGGACGAAGTAAACG-3’
AGGTTATGA-3’ 5’-CCAGAGTGGCGAGGACATG-3’
CTCAAAA-3’ 5’-GTAAAGAAAGGCACACCGAAGAG-3’
CAAATTTAA-3’ 5’-CCGTTTGCCAGAGCTGTGTA-3’
CCATCCT-3’ 5’-TCCTGTCTTCTCCTCCTCTGTGT-3’
GTCTACAC-3’ 5’-AAGGACACCACCAGCATGAAG-3’
CTTACAGCAA-3’ 5’-GGCACAGTCACGGGTCATG-3’
TACATC-3’ 5’-CGTTCCCGTTCTTCAGGTATCT-3’
TTCTG-3’ 5’-ATTTCTTGAGGTCGGCGATCT-3’
AAGAAGCT-3’ 5’-GTTCGGATTCCTGTCTCATCTCA-3’
TTCTTTGA-3’ 5’-CCACGCTGAGTTTCTCATGTTC-3’
TGACGTTCT-3’ 5’-TGGCATTCACTGCTCGAATTC-3’
GTCATGTTTCC-3’ 5’-GCTTTGATTGCCTGGTTGTCA-3’
AATGA-3’ 5’-TGACCACGACGATGATGAAAAC-3’
CAGTTTCT-3’ 5’-TCACCGTCCCATTGACAATG-3’
GTCTGAA-3’ 5’-CACGCCAAGCTTTCCCTTT-3’
CTGCCAGATA-3’ 5’-AAGGTACAGTCAGCTCGGCAGTA-3’
CTGAGATC-3’ 5’-CATCGGCAATGCTGTGGTAA-3’
AGCTGTATT-3’ 5’-CTGGTTTTTCCTGAGGAAGGTAGAG-3’
AAACG-3’ 5’-GTTGCCCGACTTCACCTTCTT-3’
GGATCTTC-3’ 5’-TTGTCAACTTCCGGTTCAGCTT-3’
ACCCTTGACA-3’ 5’-CCACAGATAGCTTGGAGGTCCTT-3’
CCTCAA-3’ 5’-ACACAATCTCCGCACCATAGAA-3’
ATTTTGG-3’ 5’-AAGTCTCCCTGGTGTCAACTCTTG-3’were e
orward
ATCAA
TTTGA
CTCCC
AACAG
CAAAG
GGCTG
AGACT
GGACA
CCAAG
AGCTC
CAGGG
TGGGC
GGACA
TCAAC
GTGCG
TGATC
GCGAT
GAGCT
GCAGA
ACCCC
TGACC
TGAGG
AGGGC
CTCAG
CCGAG
AGTAT
CATCC
AAGAA
TAGGC
CGACG
TTCTT
ACGGCthere is apparent contractile dysfunction), and 14 weeks
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tile function has been improved), and transcriptome anal-
ysis was performed. When time points 1 and 2 were
compared, 381 genes differentially were regulated, of
which 212 were up-regulated and 169 were down-regu-
lated. When time points 2 and 3 were compared, 328
genes differentially were regulated, of which 162 genes
Figure 1. Short-term Akt activation improves contractile function in pressure
overload–induced heart failure. A: Temporal profile of DOX treatment, AAC
operation, and echocardiography. B: Echocardiography. Top panels: rep-
resentative M-mode recordings; bottom panels: posterior wall thickness
(PWT), left ventricular end-diastolic dimension (LVDd), and percentage frac-
tional shortening (%FS). C, control animals; D, DTG animals. *P  0.01.
Figure 2. Short-term Akt activation improves contractile function in ADR-
induced heart failure. A: Temporal profile of DOX treatment, ADR treatment,
and echocardiography. B: Echocardiography. Top panels: representative
M-mode recordings; bottom panels: posterior wall thickness (PWT), left
ventricular end-diastolic dimension (LVDd), and percentage fractional short-
ening (%FS). C, control animals; D, DTG animals. *P  0.05, **P  0.01.were up-regulated and 166 genes were down-regulated
(Figure 3A). Venn diagram analysis revealed that the
expression of 619 transcripts differentially were regu-
lated, of which 291 genes differentially were regulated
only when heart failure was developing, 238 genes dif-
ferentially were regulated only when heart failure was
improving, and 90 genes differentially were regulated
during both of these processes (Figure 3B). Differential
expression of genes with a fold change more than 2.0
or less than 2.0 with a P value less than 0.01 were
confirmed by qPCR and are listed in Tables 2 and 3.
Categorization of differentially regulated genes using
Gene Ontology Analysis revealed that genes associated
with cell death and tissue development were up-regu-
lated during heart failure progression, which was attenu-
ated by Akt activation. Conversely, genes associated with
cancer, carbohydrate metabolism, and cell cycle were
up-regulated when heart failure was improving by Akt
activation (Figure 3C). Biological network analysis of dif-
ferentially expressed transcripts performed using Inge-
nuity Pathways Analysis revealed a set of genes, catego-
rized as cell “death network,” with significant alterations
in the expression levels at 12 weeks of age, 4 weeks after
AAC, when there is apparent contractile dysfunction (see
Supplemental Figure S1 at http://ajp.amjpathol.org). After
2 weeks of Akt activation, these alterations in the expres-
sion levels of a specific set of genes were attenuated or
Figure 3. Transcriptome analysis of DTG hearts after AAC and Akt activa-
tion. A: Temporal profile evaluation of transcripts that are expressed differ-
entially at time points 4 weeks after AAC (12 weeks) and 2 weeks after
Akt-ON (14 weeks). B: Venn diagram representing the sets of transcripts that
are regulated differentially 4 weeks after AAC (12 weeks) and 2 weeks after
Akt-ON (14 weeks). C: Categorization of differentially expressed transcripts
4 weeks after AAC (12 weeks) and 2 weeks after Akt-ON (14 weeks) revealed
by Ingenuity.in some cases reversed (see Supplemental Figure S2 at
Akt Improves Contractility 1973
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also identified a network of genes categorized as an
“Akt pathway” that differentially are regulated 2 weeks
after Akt activation, which support the authenticity of
this type of analysis (see Supplemental Figures S3 and
S4 at http://ajp.amjpathol.org). Names and symbols of
the transcripts that are regulated differentially in Sup-
plemental Figures S1 and S2 and in Supplemental Fig-
ures S3 and S4 are summarized in Supplemental Table
S1 (available at http://ajp.amjpathol.org). Taken to-
gether, categorization and biological network analysis
suggest that alterations in the expression levels of
genes associated with cell death may be involved in
the positive inotropic effects of Akt activation in the
setting of heart failure.
Table 2. Summary of Transcripts Identified by Microarray and C
(Before AAC) and 12 Weeks (4 Weeks After AAC)
Transcript name (mic
Histocompatibility 2, L region
Glucosaminyl (N-acetyl) transferase 1, core 2
Ninjurin 1
Actin 1
Cullin 5
Phospholipase A2, group IIC
BCL2-like 11
Carboxylesterase 3
Fibroblast growth factor 4
Zinc finger protein 352
Bone morphogenetic protein 8b
Insulin-like growth factor binding protein 1
SRY-box containing gene 4
ATP-binding cassette, subfamily A (ABC1), member 4
Table 3. Summary of Transcripts Identified by Microarray and C
(4 Weeks After AAC) and 14 Weeks (2 Weeks After Ak
Transcript name (mic
ATP-binding cassette, subfamily A (ABC1), member 4
Mitogen-activated protein kinase 13
Cyclin B2
Tenascin C
Cartilage intermediate layer protein, nucleotide
pyrophosphohydrolase
Thymoma viral proto-oncogene 1
Procollagen, type V, 1
Insulin-like growth factor binding protein 5
Follistatin-related protein
Bone morphogenetic protein 8b
Thrombospondin 1
Cytokine receptor-like factor 1
Calsequestrin 1
Zinc finger protein 352
Fast skeletal myosin alkali light chain
Procollagen, type VIII, alpha 1
Fibrillin 1
Myotrophin
Gap junction membrane channel protein  1
Prostaglandin D2 synthase
Carboxylesterase 3
Glucosaminyl (N-acetyl) transferase 1, core 2
Myomesin 2 Discussion
Unlike pathologic cardiac hypertrophy observed in pa-
tients with hypertension or valvular heart diseases, phys-
iologic cardiac hypertrophy as observed in trained ath-
letes or during normal postnatal growth is associated with
maintained or enhanced contractile function.
By using an inducible TG system in which cardiac Akt
signaling can be turned on or off at desired time points,
we previously showed that short-term Akt activation in the
adult heart induces a physiologic form of cardiac hyper-
trophy.35 Because cardiac hypertrophy can be beneficial
for the heart through reduction of wall stress, we hypoth-
esized that physiologic hypertrophy induced by short-
term Akt activation might improve contractile function in
d by qPCR as Differentially Regulated Between 8 Weeks
change
ys), P  0.01
Fold change
(qPCR), P  0.01
Accession
code
Transcript
symbol
16.2 12.2 BC023409 H2-L
4.7 3.7 NM173442 Gcnt1
3.7 2.0 NM013610 Ninj1
2.4 2.0 NM009606 Acta1
2.1 2.1 NM027807 Cul5
2.1 4.7 NM008868 Pla2g2c
2.2 2.4 NM009754 Bcl2l11
2.5 3.0 NM053200 Ces3
2.6 3.1 NM010202 Fgf4
3.1 2.5 NM153102 Zfp352
3.7 4.4 NM007559 Bmp8b
4.3 5.9 NM008341 Igfbp1
4.9 4.0 NM009238 Sox4
28.8 15.8 NM007378 Abca4
d by qPCR as Differentially Regulated Between 12 Weeks
change
ys), P  0.01
Fold change
(qPCR), P  0.01
Accession
code
Transcript
symbol
13.8 11.4 NM007378 Abca4
9.7 10.8 NM011950 Mapk13
7.1 5.5 NM007630 Ccnb2
6.5 4.8 NM011607 Tnc
6.1 6.5 NM173385 Cilp
4.2 6.6 NM009652 Akt1
3.5 4.6 NM015734 Col5a1
3.0 2.1 NM010518 Igfbp5
2.9 1.9 NM008047 Fstl
2.8 3.1 NM007559 Bmp8b
2.7 3.0 NM011580 Thbs1
2.7 3.1 NM018827 Crlf1
2.5 3.5 NM009813 Casq1
2.3 2.9 NM153102 Zfp352
2.2 2.4 NM021285 Myl1
2.2 2.8 NM007739 Col8a1
2.1 2.6 NM007993 Fbn1
2.1 2.0 NM008098 Mtpn
2.4 5.5 NM010288 Gja1
3.2 5.2 NM008963 Ptgds
5.2 3.2 NM053200 Ces3
5.6 6.6 NM173442 Gcnt1onfirme
Fold
roarra












onfirme
t-ON)
Fold
roarra






















10.8 17.0 NM008664 Myom2
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ent murine heart failure models (pressure overload– or
ADR-induced heart failure models) and showed that tran-
sient Akt activation after the establishment of heart failure
improved contractility in both cases. This experiment is
relevant because it mimics the clinical situation in which
therapeutic intervention is started after the onset of heart
failure, and has been difficult to perform with conven-
tional knockout or TG mice in which deletion or overex-
pression of a specific gene is initiated during early em-
bryogenesis. It was rather unexpected, however, that the
transient Akt activation attenuated contractile dysfunction
at earlier time points when no apparent hypertrophy was
observed. This clearly indicates that the beneficial effect
of Akt on contractility is independent of its effect to pro-
mote physiologic cardiac hypertrophy. Thus, although
transient Akt activation does improve contractile function
in the failing heart, this improvement is not caused by a
reduction in wall stress by Akt-mediated physiologic hy-
pertrophy. Of note, short-term Akt activation does not
affect contractile function when Akt is turned on in normal
hearts,35 indicating that the beneficial effect of Akt is
specific to failing hearts. This raises the question as to the
mechanism by which transient Akt activation has positive
inotropic effects in the setting of heart failure.
Previous studies have associated Akt activation with
pathologic cardiac hypertrophy. It recently was shown in
the canine congestive heart failure/cardiac recovery
model that phosphatidylinositol 3K and phosphatidyl-
inositol 3K expressions increase during the congestive
heart failure and cardiac recovery phases, respec-
tively.40 The study went on to extrapolate that, based on
the measured increase of phosphatidylinositol 3K/Akt
during the experimental recovery phase, the phosphati-
dylinositol 3K/Akt signaling pathway potentially plays a
role in compensatory cardiac hypertrophy. However, this
and other studies linking Akt and pathologic cardiac hy-
pertrophy generally were based on constitutively active
forms of the Akt pathway. In contrast, our model indicates
that contractile improvements after heart failure may not
be completely linked with hypertrophic growth, as evi-
denced by the lack of hypertrophy (heart rate/body
weight) seen in our model. We do recognize, however,
that any direct comparison of experimental results must
be viewed with caution because of differences in the
experimental models. Therefore, echocardiography was
chosen as an outcome marker because it is a well-estab-
lished technique for measuring cardiac function and thus
allows our work to be compared directly with previous
works in which cardiac recovery was associated with
hypertrophy.
In our previous study, we showed that short-term Akt
activation enhances vascular endothelial growth factor
secretion from the myocardium and promotes coronary
angiogenesis, which is required for the maintenance of
cardiac function during Akt-induced physiologic heart
growth: blocking the vascular endothelial growth factor
signal during short-term Akt activation results in early
transition from physiologic to pathologic hypertrophy
and contractile dysfunction.35 It also has been shown
that myocardial capillary density is decreased in heartssubjected to pressure overload.41 Therefore, one pos-
sible explanation for the Akt-mediated positive inotro-
pic effect is that Akt induces vascular endothelial
growth factor expression in cardiac muscle cells,
thereby increasing the otherwise reduced capillary
density in failing hearts. A second possibility is that Akt
modulates Ca2 handling in cardiac myocytes and
enhances contractility. It has been shown that Akt in-
creases the protein expression levels of sarcoplasmic
reticulum calcium ATPase 2 (SERCA2) in TG mice
overexpressing constitutively active Akt42 or in rat
hearts infected with Akt adenoviruses.43 Because over-
expression of SERCA2 has been shown to improve
contractile function in heart failure models,44 Akt may
show positive inotropic effects by increasing the ex-
pression levels of SERCA2. Previous investigations,45
among others, have shown a link between activation of
the phosphatidylinositol 3K/Akt pathway and SERCA2a
regulation. Although the scope of our investigations did
not specifically include measurements of SERCA2a or
other calcium-regulating proteins, it seems more than
likely that in light of the aforementioned investigations,
Akt-dependent regulation of SERCA2a is a potential
mechanism for affecting myocyte contractility. More-
over, the potential mechanisms responsible for our
model’s improved cardiac contractility will be the sub-
ject of our next series of investigations. A third possi-
bility suggested by our transcriptome analysis is that
Akt improves contractile function by suppressing cell
death in the failing heart. Several lines of evidence
support the notion of a causal role of apoptosis in heart
failure. It was shown that even low levels of cardiomy-
ocyte apoptosis, induced by procaspase-8, led to le-
thal dilated cardiomyopathy in TG mice, and that this
phenotype was prevented by treatment with caspase
inhibitor.46 Caspase inhibitor treatment also amelio-
rated the development of heart failure in Gq TG
mice.47 Moreover, loss of gp130-mediated cell survival
signals led to early transition from adaptive cardiac
growth to heart failure in response to pressure over-
load.48 Given that Akt strongly promotes cell survival
through phosphorylation of multiple downstream tar-
gets including forkhead transcription factor or BCL-2
antagonist of cell death,49 improved contractile func-
tion by inducible expression of Akt in the heart may be
owing in part to its prosurvival effects. Collectively,
transient activation of Akt signaling in cardiac muscle
cells attenuates contractile dysfunction in the failing
heart, presumably through multiple mechanisms in-
cluding modulation of coronary angiogenesis, Ca2
handling, and cell survival.
In the clinical setting, Akt is not a suitable therapeu-
tic target for patients with heart failure because sus-
tained activation of Akt is deleterious for the heart,
presumably through induction of extensive cardiac hy-
pertrophy.31,35 Because the positive inotropic effects
of Akt can be separated from its growth-promoting
effects, downstream substrates of Akt kinase that me-
diate its cardioprotective effects may be promising
therapeutic targets for heart failure.
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